BFAI
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent (SSRA) and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran. The drug was patented by Matthew Baggott and Tactogen in 2022.
BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent (SSRA) and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran. The drug was patented by Matthew Baggott and Tactogen in 2022. ==See also== Substituted 2-aminoindane 6-APB 5-MAPB ==External links== BFAI - Isomer Design
Text derived from https://en.wikipedia.org/w/index.php?oldid=1322829570 under CC BY-SA 4.0; modifications have been made.